Merck to Participate at the Citi 2016 Global Healthcare Conference
Get Alerts MRK Hot Sheet
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 2.6%
EPS Growth %: +47.1%
Join SI Premium – FREE
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, is scheduled to participate at the Citi 2016 Global Healthcare Conference in New York on Dec. 7, 2016 at 12:35 p.m. EST.
Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.
About Merck
For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
View source version on businesswire.com: http://www.businesswire.com/news/home/20161206005156/en/
Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri
Loxam, 908-740-1986
Amy Klug, 908-740-1898
Source: Merck
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for NSCLC
- CFIUS Accepts Re-filed Notice for Proposed Sale of The Kinetic Group to CSG
- Empire Petroleum (EP) Announces Modification of Terms of Previously Announced Rights Offering
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Citi, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!